University of South Florida

Saneron Ccel Therapeutics, Inc.

Universidade Federal De São Paulo - Unifesp

Cryopraxis Criobiologia Ltda.

Stemco Biomedical, Inc.

Alison Elizabeth Willing

Paul R Sanberg

Daniel D Richard

Juan Sanchez-Ramos

Keith R Pennypacker

Jon Clarence Antilla

Svitlana Garbuzova-Davis

Javier Cuevas

Andrew E Balber

Tracy Gentry

Michelle Cortes-Salva

Nelson Americo Hossne, Jr

Adriana Invitti

Cyndy Davis-Sanberg

Nicole Kuzmin-Nichols

Nelson Hossne

The present invention is directed to compositions and methods for treatment of ischemic diseases and conditions, particularly myocardial, CNS/brain and limb ischemia. More particularly, the present invention provides methods of treating disorders by administering monocytes obtained from blood, including umbilical cord blood, peripheral blood, or bone marrow to an individual in need of treatment, wherein the drug is administered to the individual at a time point specifically determined to provide therapeutic efficacy. In one embodiment, the cells are for injection into ischemic myocardium for the treatment of angina.

Ischemic tissue cell therapy

The present invention relates to the use of umbilical cord blood cells from a donor or patient to provide neural cells which may be used in transplantation. The isolated cells according to the present invention may be used to effect autologous and allogeneic transplantation and repair of neural tissue, in particular, tissue of the brain and spinal cord and to treat neurodegenerative diseases of the brain and spinal cord.

Human cord blood as a source of neural tissue repair of the brain and spinal cord

Oligodendrocytes (OLs), the predominant cell type found in cerebral white matter, are essential for structural integrity and proper neural signaling. Very little is known concerning stroke-induced OL dysfunction. Infusion of human umbilical cord blood (HUCB) cells protects striatal white matter tracts in vivo and directly protects mature primary OL cultures from oxygen glucose deprivation (OGD). Microarray studies of RNA prepared from OL cultures subjected to OGD and treated with HUCB cells showed an increase in the expression of 33 genes associated with OL proliferation, survival, and repair functions, such as myelination. Immunohistochemistry showed antioxidant protein expression was upregluated in the ipsilateral white matter tracts of rats infused with HUCB cells 48 hrs after middle cerebral artery occlusion (MCAO). These results show expression of genes induced by HUCB cell therapy that could confer oligoprotection from ischemia.

Use of endogenous antioxidant proteins in the treatment of stroke

A method of treating stroke by administration of a novel sigma agonist is presented. Twenty-four hours after MCAO, systemic administration of several novel sigma agonists including: Bromo-DTG; Chloro-DTG; N,N'-di-1-Naphthylguanidine hydrochloride (NAGH); N,N&#x2032;-di-p-Nitrophenylguanidine HCL (NAD) or vehicle were injected subcutaneously daily for 3 days. Rats treated with Bromo-DTG and Chloro-DTG had no significant improvements in any of the motor or cognitive tests while NAGH treated rats showed improved vertical movement and had significantly less motor asymmetry and bias than vehicle treated rats. Sigma receptor agonist NAGH also was found to exert its long-term neuroprotective effects by preserving both gray matter and white matter tracts. Both NAD and NAGH, when administered 24 hours after experimental stroke, reduced neural damage and enhanced behavioral recovery thirty days later which suggests that NAGH and NAD potentially extend the therapeutic window of stroke several fold over the current treatments.

N,N'-di-1 naphthylguanidine HCl (NAGH) and N,N&#x2032;-di-p-nitrophenylguanidine HCl (NAD) treatment for stroke at delayed timepoints

A method of treating a patient with a neurodegenerative disease, such as ALS, using progenitor cells isolated from human umbilical cord blood. Non-invasive transplantation of aldehyde dehydrogenase (ALDH) expressing progenitor cells provides cell replacement and protection of motor neurons.

Treating amyotrophic lateral sclerosis (ALS)with isolated aldehyde dehydrogenase-positive umbilical cord blood cells

Human cord blood as a source of neural tissue for repair of the brain and spinal cord

Growing community of inventors

Tampa, FL, United States of America

Alison Elizabeth Willing